TCRX · TScan Therapeutics, Inc.
$0.22
+0.01 (+6.57%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“However, substantial doubt about the Company's ability to continue as a going concern exists. ... These conditions raise substantial doubt about the Company's ability to continue as a going concern. ... Therefore, substantial doubt about the Company's ability to continue as a going concern has not been alleviated.”View the 10-Q filed Aug 12, 2026
Market Cap
$14.25M
Shares
67.78M
Volume · Oct 20
559.56K
Avg daily vol (3M)
763.51K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.22
Open$0.21
Day$0.21–0.23
52W close$0.21–2.52
Avg vol 30d722K
Short int2.5M · 3.7% float · 3.3d
Short vol67%
Last earningsMay 6, 2025
DataJul 2021–Oct 2026
Filing10-Q · Aug 12
Up next
filed Aug 12, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$7.11M
Trailing 12 months
Net income (TTM)
−$117.71M
Trailing 12 months
Revenue growth YoY
-65.8%
Year over year
Operating margin
-1,695.1%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-756.5%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$67.38M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.2%
Year over year · more shares
Price change (1Y)
-91.5%
Trailing year
Short interest
3.7%
Latest settlement · 3.3 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 17.3 · elevated
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−75%
below
Price vs 50-day avg
−50%
below
RSI (14)
30
neutral
MACD trend
Positive
52-week position
1%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−37%
trailing
6-month return
−81%
trailing
YTD return
−78%
this year
Relative strength
−89%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.67% of float · ▲ +9.0% MoM · 3.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
60 holders — mid 3-yr range
Squeeze score
45
elevated · 0–100
Fundamentals
Revenue growth
+267%
Y/Y
EPS growth
+12%
Y/Y
Free cash flow
$-139.7M
Balance sheet
$119.9M
net cash
Quant / Vol
risk profile
Volatility
99%
annualized · 1-yr
Max drawdown
−92%
past year
ATR
14.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−75%
Bearish
Price vs 50-day avg
−50%
Bearish
RSI (14)
30
Neutral
MACD trend
Positive
Bullish
52-week position
1%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +6 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.67% of float · ▲ +9.0% MoM · 3.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
60 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0
Now $0 · 1%
Range high $3
vs 200-day avg -75%
vs 50-day avg -50%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| issued and outstanding shares of common stock | 67,779,255 | Q2 2026 | — |
| non-voting common stock | 4,276,588 | Q2 2026 | — |
| outstanding pre-funded warrants | 62,246,707 | Q2 2026 | — |
| Pro forma outstanding shares | 130,025,962 | Q2 2026 | — |
| voting common stock | 63,502,667 | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TCRX
this stock
TScan Therapeutics, Inc.
|
$14.25M | -77.6% | +266.7% | — | 3.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.07B | +13.5% | +46.2% | 29.9 | 1.8% |
|
MRNA
Moderna, Inc.
|
$90.58B | +720.9% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.51B | +4.6% | +20.8% | 19.4 | 2.1% |
|
CSLLY
Csl Ltd
|
$66.34B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
SEC Filings
Latest
8-K
- Filed
- Oct 16, 2026
- This year
- 21
TScan Therapeutics, Inc. reported that directors Garry Nicholson and Gabriela Gruia, M.D. resigned from its Board effective October 13, 2026, with no disagreement cited, and Stephen Biggar and R. Keith Woods were appointed to the Nominating and Corporate Governance Committee.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TCRX | +3.4% | -36.9% | -80.5% | -28.8% | -77.6% |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | +4.5% | -36.3% | -88.6% | -29.6% | -90.4% |